India's Caplin Point Lab near 3-month high on FDA nod to new drug

Caplin Point Laboratories

12/05/2023 08:25

** Shares of Caplin Point Laboratories Ltd  CAPL.NS  rise as
much as 3.5% to 709.70 rupees, hitting their highest since Feb.
14
    ** Pharmaceutical co's subsidiary Caplin Steriles gets final
approval from United States Food and Drug Administration for
Ketorolac Tromethamine Injection USP, an anti-inflammatory drug
for moderately severe acute pain
    ** Stock trading above 50- and 100-day moving averages
    ** MACD line above signal line since April 3, suggesting
bullish momentum
    ** Stock posts sharpest intraday pct gain since April 27;
set to snap second session of consecutive gains, if trends hold
    ** More than 135,860 shares change hands by 12:30 p.m. IST,
1.2x the 30-day avg
    ** Stock down 3.9% so far this year, up to last close

 (Reporting by Dimpal Gulwani in Bengaluru)
 ((dimpal.gulwani@thomsonreuters.com))